These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Adiponectin in autoimmune diseases. Toussirot É; Binda D; Gueugnon C; Dumoulin G Curr Med Chem; 2012; 19(32):5474-80. PubMed ID: 22876925 [TBL] [Abstract][Full Text] [Related]
3. Prevalence of systemic autoimmune rheumatic diseases and clinical significance of ANA profile: data from a tertiary hospital in Shanghai, China. Yang Z; Ren Y; Liu D; Lin F; Liang Y APMIS; 2016 Sep; 124(9):805-11. PubMed ID: 27328803 [TBL] [Abstract][Full Text] [Related]
4. Serum uric acid increases in patients with systemic autoimmune rheumatic diseases after 3 months of treatment with TNF inhibitors. Hasikova L; Pavlikova M; Hulejova H; Kozlik P; Kalikova K; Mahajan A; Herrmann M; Stiburkova B; Zavada J Rheumatol Int; 2019 Oct; 39(10):1749-1757. PubMed ID: 31363829 [TBL] [Abstract][Full Text] [Related]
5. Comparisons of neutrophil-, monocyte-, eosinophil-, and basophil- lymphocyte ratios among various systemic autoimmune rheumatic diseases. Yang Z; Zhang Z; Lin F; Ren Y; Liu D; Zhong R; Liang Y APMIS; 2017 Oct; 125(10):863-871. PubMed ID: 28766758 [TBL] [Abstract][Full Text] [Related]
6. Novel insights into systemic autoimmune rheumatic diseases using shared molecular signatures and an integrative analysis. Hudson M; Bernatsky S; Colmegna I; Lora M; Pastinen T; Klein Oros K; Greenwood CMT Epigenetics; 2017 Jun; 12(6):433-440. PubMed ID: 28387599 [TBL] [Abstract][Full Text] [Related]
7. Prevalence of anti-NT5C1A antibodies in Japanese patients with autoimmune rheumatic diseases in comparison with other patient cohorts. Muro Y; Nakanishi H; Katsuno M; Kono M; Akiyama M Clin Chim Acta; 2017 Sep; 472():1-4. PubMed ID: 28687351 [TBL] [Abstract][Full Text] [Related]
8. Rituximab in systemic autoimmune rheumatic diseases: indications and practical use. Berghen N; Vulsteke JB; Westhovens R; Lenaerts J; De Langhe E Acta Clin Belg; 2019 Aug; 74(4):272-279. PubMed ID: 30253707 [No Abstract] [Full Text] [Related]
9. Airborne pollutants as potential triggers of systemic autoimmune rheumatic diseases: a narrative review. Celen H; Dens AC; Ronsmans S; Michiels S; De Langhe E Acta Clin Belg; 2022 Oct; 77(5):874-882. PubMed ID: 34666637 [TBL] [Abstract][Full Text] [Related]
10. Filling the gaps in SARDs research: collection and linkage of administrative health data and self-reported survey data for a general population-based cohort of individuals with and without diagnoses of systemic autoimmune rheumatic disease (SARDs) from British Columbia, Canada. McCormick N; Reimer K; Famouri A; Marra CA; Aviña-Zubieta JA BMJ Open; 2017 Jun; 7(6):e013977. PubMed ID: 28637725 [TBL] [Abstract][Full Text] [Related]
11. Exercise as a therapeutic tool to counteract inflammation and clinical symptoms in autoimmune rheumatic diseases. Perandini LA; de Sá-Pinto AL; Roschel H; Benatti FB; Lima FR; Bonfá E; Gualano B Autoimmun Rev; 2012 Dec; 12(2):218-24. PubMed ID: 22776785 [TBL] [Abstract][Full Text] [Related]
13. Association between serum/plasma adiponectin levels and immune-mediated diseases: a meta-analysis. Zhang MY; Dini AA; Yang XK; Li LJ; Wu GC; Leng RX; Pan HF; Ye DQ Arch Dermatol Res; 2017 Oct; 309(8):625-635. PubMed ID: 28702765 [TBL] [Abstract][Full Text] [Related]
19. Cancer Risk in Patients With Inflammatory Systemic Autoimmune Rheumatic Diseases: A Nationwide Population-Based Dynamic Cohort Study in Taiwan. Yu KH; Kuo CF; Huang LH; Huang WK; See LC Medicine (Baltimore); 2016 May; 95(18):e3540. PubMed ID: 27149461 [TBL] [Abstract][Full Text] [Related]
20. Adiponectin: a biomarker for rheumatoid arthritis? Chen X; Lu J; Bao J; Guo J; Shi J; Wang Y Cytokine Growth Factor Rev; 2013 Feb; 24(1):83-9. PubMed ID: 22910140 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]